15-deoxy-δ12,14-Prostaglandin D2-d9 (Synonyms: 15-deoxy-Δ12,14-PGD2-d9) |
| Catalog No.GC46444 |
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2738376-68-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
15-deoxy-δ12,14-Prostaglandin D2 (15-deoxy-δ12,14-PGD2-d9) is intended for use as an internal standard for the quantification of 15-deoxy-δ12,14-PGD2 by GC- or LC-MS. 15-deoxy-δ12,14-PGD2 is a metabolite of PGD2 .1 It is an agonist of PGD2 receptor 2 (DP2) that binds DP2 (Ki = 50 nM for the mouse receptor expressed in HEK293 cell membranes) and induces activation of eosinophils (EC50 = 8 nM).2,3 It also stimulates the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ) and induces PPARγ-mediated transcription in a reporter assay when used at a concentration of 5 µM.1 15-deoxy-δ12,14-PGD2 is cytotoxic to L1210 murine leukemia cells (IC50 = 0.3 µg/ml).4 It inhibits ADP-induced platelet aggregation (IC50 = 320 ng/ml) less potently than PGD2.5
1.SÖderstrÖm, M., Wigren, J., Surapureddi, S., et al.Novel prostaglandin D2-derived activators of peroxisome proliferator-activated receptor-γ are formed in macrophage cell culturesBiochim. Biophys. Acta1631(1)35-41(2003) 2.Hata, A.N., Zent, R., Breyer, M.D., et al.Expression and molecular pharmacology of the mouse CRTH2 receptorJ. Pharmacol. Exp. Ther.306(2)463-470(2003) 3.Monneret, G., Li, H., Vasilescu, J., et al.15-Deoxy-δ12,14-prostaglandins D2 and J2 are potent activators of human eosinophilsJ. Immunol.168(7)3563-3569(2002) 4.Forman, B.M., Tontonoz, P., Chen, J., et al.15-Deoxy-δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγCell83(5)803-812(1995) 5.Bundy, G.L., Morton, D.R., Peterson, D.C., et al.Synthesis and platelet aggregation inhibiting activity of prostaglandin D analoguesJ. Med. Chem.26(6)790-799(1983)
| Cas No. | 2738376-68-4 | SDF | |
| Synonyms | 15-deoxy-Δ12,14-PGD2-d9 | ||
| Canonical SMILES | O=C1/C([C@@H](C/C=C\CCCC(O)=O)[C@@H](O)C1)=C/C=C/CC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H] | ||
| Formula | C20H21D9O4 | M.Wt | 343.5 |
| Solubility | DMF: 100mg/mL,DMSO: 20mg/mL,Ethanol: 75mg/mL,Methyl Acetate: 1 mg/ml,PBS (pH 7.2): 2mg/mL | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9112 mL | 14.556 mL | 29.1121 mL |
| 5 mM | 0.5822 mL | 2.9112 mL | 5.8224 mL |
| 10 mM | 0.2911 mL | 1.4556 mL | 2.9112 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *